Daewoong Pharma's botulinum toxin Nabota wins approval from Australia

Daewoong Pharmaceutical said on Wednesday that its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) won approval in Australia on Jan. 13.

The item that received approval this time is Nuceiva 100 units whose application to the Australian authorities had been made by Nabota's cosmetic indication partner Evolus of the United States in Dec. 2021.

The South Korean company explained that it plans to launch Nuceiva in Australia in the second half of this year or the first half of next year.

With the latest product approval, Nabota has been approved in 61 countries across the world.

"We are delighted to introduce Nuceiva, which has excellent stability and quality, to Australian consumers. We will exert efforts to launch it in Australia as soon as possible, while obtaining approval and releasing it in many countries, including China, this year," said Park Seong-soo, vice president of Daewoong Pharmaceutical.

Write to Jung-Eun Kim at likesmile@hankyung.com